Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod (SUNBEAM™) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 – 7th Joint ECTRIMS – ACTR
Go back to Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod (SUNBEAM™) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 – 7th Joint ECTRIMS – ACTR| Celgene Corp. (NASDAQ: CELG) | Delayed: 108.24 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $108.24 | 52 Week High | $127.00 | |||
| Open | $7.85 | 52 Week Low | $93.05 | |||
| Day High | $108.24 | P/E | 32.12 | |||
| Day Low | $108.24 | EPS | $3.37 | |||
| Volume | 0 | |||||
